Received for publication June 26, 2006.
Revised September 5, 2006.
Accepted for publication September 6, 2006.

Oral Treatment with Rofecoxib Reduces Hippocampal Excitotoxic Neurodegeneration

Abstract

The purpose of this study was to determine whether the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib could effectively prevent hippocampal neuronal injury in an animal model of excitotoxic neurodegeneration. COX-2 protein levels increased between 3 and 6 hr, peaked at 12 hr and declined to near baseline levels 24 hr after injection of N-methyl-D-aspartate (NMDA; 18 nmol) into the CA1 region of the left hippocampus. Mice fed, ad libitum, a control rodent diet for four days before and three days after injection of NMDA demonstrated marked neuronal loss in the primary cell layers of the ipsilateral CA1, CA3, and dentate gyrus (50, 30, and 20% cell loss, respectively). This injury was potently and dose-dependently reduced by feeding animals a diet standardized to deliver 15 or 30 mg/kg rofecoxib per day. Neurodegeneration in the CA1 region was reduced by 30.1 ± 5.6% and 51.5 ± 9.0%, respectively; in the CA3 by 64.6 ± 12.4 and 69.0 ± 14.1%, respectively; and in the dentate gyrus by 47.8 ± 15.2% and 58.0 ± 18.2%, respectively. Moreover, rofecoxib chow slightly but significantly reduced injury-induced brain edema. These findings demonstrate that rofecoxib can ameliorate excitotoxic neuronal injury in vivo and, as such, may be a particularly promising pharmaceutical for the treatment of neurological diseases associated with over-activation of NMDA receptors.

Key words: cyclooxygenase, excitotoxicity, hippocampus, mouse, neurodegeneration, rofecoxib

This article has been cited by other articles:

				B. Bauer, A. M. S. Hartz, A. Pekcec, K. Toellner, D. S. Miller, and H. Potschka Seizure-Induced Up-Regulation of P-Glycoprotein at the Blood-Brain Barrier through Glutamate and Cyclooxygenase-2 Signaling Mol. Pharmacol., May 1, 2008; 73(5): 1444 - 1453. [Abstract] [Full Text] [PDF]